

**CHANGE OF STATUS REPORT  
NATIONAL INSTRUMENT 51-102  
RESPECTING CONTINUOUS DISCLOSURE OBLIGATIONS**

To: British Columbia Securities Commission  
Alberta Securities Commission  
Ontario Securities Commission

Pursuant to Section 11.2 of National Instrument 51-102 respecting *Continuous Disclosure Obligations* (“**NI 51-102**”), notice is hereby given that, effective February 13, 2024, the common shares of Awakn Life Sciences Corp. (the “**Corporation**”) ceased trading on CBOE Canada Inc. and commenced trading on the Canadian Securities Exchange and, accordingly, the Corporation became a “venture issuer” as such term is defined under NI 51-102.

Dated this 24<sup>th</sup> day of September, 2024.

**AWAKN LIFE SCIENCES CORP.**

*“Jonathan Held” (Signed)*

**Jonathan Held**  
**Chief Financial Officer**